You are here: Industry Insights > Takeda

News List

Takeda to divest dry eye drug to Novartis in $5.3bn deal pharmaceutical-technology
May 10, 2019
Takeda Pharmaceutical has signed an agreement to sell its Xiidra 5% drug to Novartis for a total consideration of up to $5.3bn.
Takeda sells Shire’s Xiidra, transfers 400 staffers to Novartis in $3.4B deal fiercepharma
May 09, 2019
Takeda is looking to lighten the huge debt burden from the Shire buyout. Novartis wants to beef up its eye medicine portfolio after the Alcon spinoff. Now, the two companies have found a deal where their needs align.
Novartis to acquire Takeda's dry eye treatment Xiidra in a deal valued at up to $5.3 billion firstwordpharma
May 09, 2019
Novartis on Wednesday announced that it has reached an agreement to purchase the assets associated with Takeda's dry eye treatment Xiidra (lifitegrast). In the deal,
Skyhawk and Takeda partner to develop small molecule drugs pharmaceutical-technology
May 08, 2019
US-based Skyhawk Therapeutics has formed a strategic alliance with Takeda Pharmaceutical to discover and develop small molecule drug candidates for multiple targets across neurodegenerative diseases.
Takeda opens drug research facility in California, US pharmaceutical-technology
May 05, 2019
Takeda Pharmaceutical Company has unveiled a new research centre in San Diego, California, US.
Takeda scouts buyers for Latin America business, a deal that could fetch $1B fiercepharma
April 08, 2019
Chatter about debt-laden Takeda looking to sell assets after the Shire megadeal just keeps coming.
EMA accepts Takeda application for subcutaneous Entyvio pharmatimes
April 04, 2019
The European Medicines Agency (EMA) has accepted Takeda’s marketing authorisation application for its subcutaneous formulation of Entyvio (vedolizumab) for maintenance therapy...
Takeda collaborates with StrideBio to develop new gene therapies pharmaceutical-technology
April 03, 2019
Takeda Pharmaceutical has entered into a collaboration and licensing agreement with US-based gene therapy company StrideBio for the development of in vivo AAV based treatments for neurological disorders.
Takeda, StrideBio to advance novel gene therapies for neuro diseases biospectrumasia
April 02, 2019
Multi-target deal will utilize StrideBio’s platform to identify unique AAV capsids for delivery of gene therapies targeting neurological diseases, including Friedreich’s Ataxia
LegoChem Biosciences, Takeda collaborate for immuno-oncology research biospectrumasia
March 25, 2019
Takeda gains certain rights to LCB’s antibody-drug conjugate (ADC) technology

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page